# Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Study · id `cardio:ct-nct02866175` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02866175](<https://clinicaltrials.gov/study/NCT02866175>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02866175

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1506 participants.

## Technical summary

Registry record NCT02866175. Randomized; no masking; primary purpose treatment. Start 2017-02-24 (actual); primary completion 2019-06-06 (actual). Results posted on 2020-05-06.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1506 participants (enrolled count; ClinicalTrials.gov record NCT02866175, source copy `cardio:ctgov-nct02866175-2020-05-06`, retrieved 2026-10-26)
- Started: 2017-02-24 (actual) (ClinicalTrials.gov record NCT02866175, source copy `cardio:ctgov-nct02866175-2020-05-06`, retrieved 2026-10-26)
- Primary completion: 2019-06-06 (actual) (ClinicalTrials.gov record NCT02866175, source copy `cardio:ctgov-nct02866175-2020-05-06`, retrieved 2026-10-26)
- Completion: 2019-06-06 (actual) (ClinicalTrials.gov record NCT02866175, source copy `cardio:ctgov-nct02866175-2020-05-06`, retrieved 2026-10-26)
- Results first posted: 2020-05-06 (ClinicalTrials.gov record NCT02866175, source copy `cardio:ctgov-nct02866175-2020-05-06`, retrieved 2026-10-26)
- Countries: Austria; Belgium; France; Germany; Hungary; Italy; Lithuania; Netherlands; Poland; Portugal; Romania; Serbia; South Korea; Spain; Switzerland; Taiwan; Ukraine; United Kingdom (ClinicalTrials.gov record NCT02866175, source copy `cardio:ctgov-nct02866175-2020-05-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02866175-2020-05-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
- Acronym: ENTRUST-AF-PCI
- Condition: Atrial Fibrillation
- Intervention (Drug): Edoxaban
- Intervention (Drug): Clopidogrel
- Intervention (Drug): Prasugrel
- Intervention (Drug): Ticagrelor
- Intervention (Drug): Vitamin K antagonist
- Lead sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Edoxaban (`cardio:edoxaban`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry intervention name matches this record: Prasugrel (`cardio:prasugrel`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry lists this organization as the lead sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (`cardio:org-daiichi-sankyo-europe-gmbh-a-daiichi-sankyo-company`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial (`cardio:pubmed-31492505`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysis (`cardio:pubmed-33098470`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 46f5586fc86a31689d4896159a711c4a1ab7c65468fa9d013e5439a243a6bfe9
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
